| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
2003-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_136b24c92e1dc12aec463913ba016552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bba622be0d8f9f2ab1ae948e0cd7a5bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53e6a3347f96c53b692fb73b0a73774c |
| publicationDate |
2004-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004142040-A1 |
| titleOfInvention |
Formulation and dosage form providing increased bioavailability of hydrophobic drugs |
| abstract |
The present invention provides a drug formulation and a dosage form. The drug formulation works to increase the bioavailability of hydrophobic drugs delivered to the gastro-intestinal tract (“GI tract”) of a desired subject. The drug formulation of the present invention is formulated as a self-emuslifying nanosuspension, which forms an emulsion in-situ upon introduction to an aqueous environment. The dosage form of the present invention may be formed using various different materials and may be configured to deliver the drug formulation of the present invention to the GI tract of a subject using any desired mechanism. A controlled release dosage form according to the present invention may be designed to deliver the drug formulation of the present invention at a desired rate over a desired period of time. If designed as a controlled release dosage form, the dosage form of the present invention may be an osmotic dosage form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020157675-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010159010-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008220076-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011229530-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006047025-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8685455-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010063142-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009042114-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006057206-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9642826-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008050450-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9034389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8993625-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471565-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006023286-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9655873-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009202643-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011071090-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006023286-A3 |
| priorityDate |
2002-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |